A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

See allHide authors and affiliations

Science Translational Medicine  23 Aug 2017:
Vol. 9, Issue 404, eaan0972
DOI: 10.1126/scitranslmed.aan0972

Could a drug for diabetes help in the treatment of hydrocephalus?

Hydrocephalus is a life-threatening condition in babies caused by raised intracranial pressure due to an increase in cerebrospinal fluid volume. Now, Botfield et al. show that the glucagon-like peptide-1 receptor (GLP-1R), known to modulate fluid homeostasis in the kidney, is expressed in human and rodent choroid plexus, the brain area responsible for cerebrospinal fluid secretion. The authors show that treating a rat model of hydrocephalus with a GLP-1R agonist reduced intracranial pressure. This suggests that GLP-1R agonists, approved for treating diabetes, could be repurposed for treating hydrocephalus and potentially other conditions characterized by raised ICP.

View Full Text

Stay Connected to Science Translational Medicine